The Economic Burden of Obesity by Glycemic Stage in the United States

被引:0
作者
Qian Li
Steven W. Blume
Joanna C. Huang
Mette Hammer
Thomas R. Graf
机构
[1] Evidera,Retrospective Observational Studies
[2] Novo Nordisk Inc,Health Economics and Outcomes Research
[3] Geisinger Health System,Population Health
来源
PharmacoEconomics | 2015年 / 33卷
关键词
Body Mass Index; Normal Body Mass Index; Body Mass Index Category; Pharmacy Cost; Healthcare Resource Utilization;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:735 / 748
页数:13
相关论文
共 81 条
  • [1] Ogden CL(2014)Prevalence of childhood and adult obesity in the United States, 2011–2012 JAMA. 311 806-814
  • [2] Carroll MD(2009)The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis BMC Public Health. 9 88-2330
  • [3] Kit BK(2014)Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status Pharmacoeconomics 16 2323-1046
  • [4] Flegal KM(2008)Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic Obesity. 36 1033-S66
  • [5] Guh DP(2013)Economic costs of diabetes in the U.S. in 2012 Diabetes Care. 36 S11-338
  • [6] Zhang W(2013)Standards of medical care in diabetes–2013 Diabetes Care. 6 327-37
  • [7] Bansback N(2013)Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review Diabetes Metab Syndr Obes. 5 34-233
  • [8] Amarsi Z(1994)The cost of obesity: the US perspective Pharmacoeconomics. 30 228-1659
  • [9] Birmingham CL(2007)Progression from newly acquired impaired fasting glusose to type 2 diabetes Diabetes Care. 23 1654-659
  • [10] Anis AH(2000)Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis Diabetes Care. 55 652-61